1 / 52

LYMPHOMAS

LYMPHOMAS. Dr. Marlene Hamilton. Objectives. What is lymphoma Brief Overview of the history How does it present clinically How do we diagnose lymphoma Hodgkin vs non-Hodgkin lymphoma Principles of treatment. Lymphoma. cancer of lymphocytes originate from T or B cells

oistin
Télécharger la présentation

LYMPHOMAS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. LYMPHOMAS Dr. Marlene Hamilton

  2. Objectives • What is lymphoma • Brief Overview of the history • How does it present clinically • How do we diagnose lymphoma • Hodgkin vs non-Hodgkin lymphoma • Principles of treatment

  3. Lymphoma • cancer of lymphocytes • originate from T or B cells • relatively common maligancies • subdivided into Hodgkin and Non-Hodgkin Lymphoma (NHL)

  4. Lymphoma History • First recognized by Thomas Hodgkin in 1832 • paper “On Some Morbid Appearances of the Absorbent Glands and Spleen” • recognized that enlarged lymph nodes could arise from primary disorder (vs infection or carcinoma) • in 1860’s Virchowdistinguished between leukemia “aleukmia” and “lymphosarcoma” • in 1871 Billroth coined term malignant lymphoma • about 1900 Reed and Sternberg identified cell classic for Hodgkin Lymphoma and pointed out importance of histopathology in the diagnosis of lymphoma

  5. Lymphoma History • In 1920’s Brill described the pathologic features of Follicular lymphoma • 1956 Rappaport developed a morphologic classification of non-Hodgkin Lymphoma • in 1972 the immunologic origin discovered by finding monotypic Ig on surface of B cell lymphomas • In 1982 a morphologic classification of NHL developed called the Working Formulation • based on grade • in 1994 a Revised European-American Lymphoma Classification (REAL) developed which classified according to T of B cell lineage • current WHO classification

  6. Which Tissues are Affected? • Lymph nodes • spleen • bone marrow • less common peripheral blood, solid organs, skin, CNS

  7. Lymphadenopathy • Enlarged lymph nodes • usually greater than 1 cm • most infectious in etiology

  8. Lymphadenopathy • Worrisome features for lymphoma • infectious work-up negative • persistent • growing • multiple sites • associated with fever • associated with night sweats • associated with weight loss

  9. Lymphadenopathy • abnormal CBCD • abnormal renal or LFTs • Differential diagnosis of lymphadenopathy • infectious cause • lymphoma • carcinoma • other rarer causes

  10. Lymphadenopathy • lymph nodes affected by lymphoma typically firm and may be rubbery • usually mobile, but may be fixed • lymph nodes often painless • lymph nodes affected by carcinoma more likely to be rock hard and fixed

  11. Clinical presentation • LN • symptoms resulting from LN impact • ex SOB from mediatinal mass, ARF from ureteric obstruction • symptoms from bone marrow infiltration • ex bleeding from thrombocytopenia, infection from neutropenia, fatigue from anemia

  12. Clinical presentation • Weight loss > 10% over 6 months • Fever >38*C • drenching night sweats • = “B” symptoms • May have associated autoimmune phenomena • ITP = immune thrombocytopenia purpura • AIHA = autoimmune hemolyic anemia May have no Symptoms

  13. Clinical presentation • Hodgkin • younger (bimodal) • often above diaphragm • moves orderly to nodal groups • more often B symptoms (ex Pel- Ebstein fever) • NHL • often older • often disseminated • no orderly spread • often disseminated at diagnosis

  14. Lymphadenopathy • To make diagnosis of lymphoma need an EXCISIONAL biopsy • pathologist needs sufficient tissue to view morphology and to perform immunostains • fine needle aspirate (FNA) insufficient • core biopsy may be acceptable • usually choose the largest lymph node to biopsy • disfavour inguinal lymph nodes • choose lymph node which is safe and accessible • if lymphadenopathy intra-abdominal may need to consider second best choice, U/S or CT guided core biopsy vs surgical excisional biopsy

  15. Lymphoma Pathology • NHL • Hodgkin Lymphoma • Specific pathology and stage are important as they determine the treatment strategy • Ann Arbor Staging- applies to both NHL and Hodgkin

  16. Lymphoma Staging • I single LN region/extranodal site • II 2/more LN regions on same side of diaphragm • III LN regions on both sides of the diaphragm • IV diffuse involvement of extralymphatic organs or sites • A no B symptoms • B • fever > 38 *C • weight loss >10% over 6 months • drenching night sweats • S spleen involvement • Bulky LN>10 cm • E extranodal

  17. Lymphoma Extranodal Sites • Can be virtually anywhere • GIT • thyroid • parotid • breast • testicle • eye • skin • Bone • brain • sinuses • ...

  18. Lymphoma Staging • History and physical • CT (neck), chest, abdomen and pelvis • Bone marrow biopsy • PET scan not routine • other in special situations (ex LP, CT head)

  19. Lymphoma other tests • LDH (NHL) • ESR (HD)

  20. NHL Lymphoma Classification • More than 40 entities • WHO subdivides into B and T or NK cell neoplasms • clinically subdivide into indolent, aggressive and very aggressive

  21. NHL Lymphoma Classification • Resultant lymphoma dependent on site

  22. NHL- Indolent B cell • Follicular lymphoma • Small Lymphocytic Lymphoma (SLL) or CLL • MALT • Splenic Marginal Zone • Marginal Zone • Waldenstrom’s Macroglobulinemia • Hairy Cell Leukemia • Follicular Lymphoma most common

  23. Follicular Lymphoma • Follicular centre is the major site B lymphocyte differentiation and proliferation • low grade, but often widespread at diagnosis • often bone marrow is involved, even if CBCD is normal

  24. Follicular Lymphoma • Follicular Lymphoma on lymph node biopsy

  25. Follicular Lymphoma • Follicular Lymphoma on bone marrow (trephine) biopsy • Good test for confirming involvement, but difficult to make an initial diagnosis on

  26. Follicular Lymphoma • BCL-2 molecular abnormality • t(14;18) • grades 1-3, with 3a and 3b • 3b considered aggressive disease

  27. Follicular Lymphoma • Prognosis based on FLIPI score • age>60 years • stage III or IV disease • high LDH • Hg<120 • 5+ nodal sites • Indolent, but incurable (except in rare circumstance) • However highly sensitive to chemotherapy and radiotherapy

  28. NHL- Aggressive B cell • Diffuse Large B cell (DLBC) Lymphoma • DLBCL, leg type • Primary Mediastinal DLBCL • Intravascular DLBCL • Plasmablastic lymphoma • High grade follicular lymphoma • Mantle cell lymphoma • DLBCL most common

  29. DLCBL • Aggressive lymphoma • without treatment, fatal within weeks to months • bone marrow usually not involved, but if it is, it is associated with an increased incidence of CNS involvement • BCL-6 positive • Potentially curable with chemotherapy • chance of cure dependent on IPI prognostic features and stage

  30. DLBCL • Diffuse effacement of the lymph node architecture, with little normal architecture remaining

  31. DLBCL • Cells positive for staining anti-CD 20

  32. DLBCL • Bone marrow involvement with DLBCL

  33. DLBCL • IPI • increased LDH • stage III or IV disease • ECOG 2-4 • >1 extranodal site • age > 60 years • Limited stage disease with IPI = 0, 5 year progression free survival 94% • Advanced stage disease with high IPI, 4 year overall survival 55%

  34. NHL- Very Aggressive B cell • Burkitt Lymphoma • Lymph node involved with Burkitt Lymphoma

  35. NHL- Indolent T cell • Mycosis fungoides • primary cutaneous CD30+ • primary cutaneous CD30- • T cell LGL • Relatively uncommon

  36. NHL- Indolent T cell • Mycosis fungoides • involves skin

  37. NHL- Aggressive T cell • Peripheral T cell unspecified • angioimmunoblastic • T/NK cell, nasal type • enteropathy associated • hepatosplenic T cell • subcutaneous panniculitis-like • anaplastic large cell CD 30+, ALK + • anaplastic large cell CD 30+, ALK – • Relatively uncommon, thank goodness!

  38. NHL- Aggressive T cell • Entropathy associated T cell lymphoma

  39. NHL- Very Aggressive T cell • T Lymphoblastic Leukemia/Lymphoma • Adult T cell Leukemia/Lymphoma) ATLL (HTLV-1 associated) • Primary CNS Lymphoma (often HIV+) • Primary Effusion Lymphoma (HIV+) • Post-transplant lymphoproliferative disorder (PTLD)

  40. Hodgkin Lymphoma • Classical • Nodular Sclerosis • Mixed cellularity • Lymphocyte Rich • lymphocyte depleted • Nodular lymphocyte predominant • Nodular Sclerosis most common • Quite potentially curable

  41. Hodgkin Lymphoma • Classic histological feature = Reed Sternberg cell

  42. Lymphoma Transformation • Lower grade lymphomas can “transform” into higher grade lymphomas • about 10% • ex DLBCL arising from follicular lymphoma • ex Hodgkin lymphoma arising from SLL • May have 2 pathologies on one surgical specimen • may have bone marrow discordance • If clinical behaviour of lymphoma changes or becomes more aggressive we will often repeat a LN biopsy, looking for transformation • Treat according to the most aggressive histology

  43. Lymphoma Etiology • Often no cause identified • immunodeficiency states • HIV • EBV • Hepatitis C • other viruses • H pylori • systemic autoimmune disorders (ex SLE) • immunosuppression in transplant patients to prevent rejection • pesticides, herbicides, dioxins

  44. Lymphoma Treatment Overview • Treatment is dependent on stage and pathology • If potentially curable we treat aggressively • If not, treatment is reserved for complications/symptoms

  45. NHL Treatment- Indolent Lymphomas • Disease is often disseminated at diagnosis • disease slow growing • Only potential curative situation is when stage I A or contiguous IIA disease • can be encompassed within a radiation field--->IFRT • may prove to have had higher stage disease than detected if recurs elsewhere with time

  46. NHL Treatment- Indolent Lymphomas • More advanced disease treat when: • symptoms • progressive/significant LN • moderate/severe splenomegaly • impending organ compromise • cytopenias • patient preference

  47. NHL Treatment- Indolent Lymphomas • Upfront treatment does not currently improve overall survival • If no symptoms follow “wait and watch” treatment approach • If need to treat usually use chemotherapy, ex R-CVP • following chemotherapy patient may have maintenance treatment, depending on the pathology

  48. NHL Treatment- Aggressive Lymphomas • Rapidly growing neoplasms • death if not treated, usually in the order of weeks to months • potentially curable • If early stage disease (I or IIA), treat with brief chemotherapy followed by IFRT • rationale for chemotherapy is to treat any “stray” disease beyond the radiation field • If advanced stage disease treat with chemotherapy alone in most cases • chemotherapy given IV, multidrug, with repeated cycles • if “bulky” disease will offer RT to site of bulk

  49. NHL Treatment- Aggressive Lymphomas • If disease recurs after appropriate treatment and the patient is relatively young, they may be a candidate for an autologous stem cell transplant for salvage treatment • Otherwise recurrence ---> palliative

  50. Hodgkin Lymphoma Treatment • Quite potentially curable • death if not treated, usually in the order of months • the lower the stage the increase chance of overall survival with therapy • Early stage disease (up to and including IIA) treat with abbreviated course of chemotherapy followed by IFRT • chemotherapy to irradiate potential disease outside of radiation field not detected by staging investigations

More Related